Ainos, Inc. (NASDAQ:AIMD) Sees Large Decline in Short Interest

Ainos, Inc. (NASDAQ:AIMD) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 122,800 shares, a decrease of 27.9% from the August 31st total of 170,400 shares. Based on an average daily volume of 521,300 shares, the short-interest ratio is presently 0.2 days. Currently, 8.4% of the company’s stock are sold short.

Ainos Stock Down 7.3 %

AIMD stock opened at $0.53 on Friday. Ainos has a twelve month low of $0.45 and a twelve month high of $4.29. The business has a 50 day moving average price of $0.60 and a two-hundred day moving average price of $0.87. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.45 and a current ratio of 1.48.

Ainos (NASDAQ:AIMD) last released its earnings results on Monday, August 5th. The company reported ($0.49) earnings per share for the quarter. Ainos had a negative net margin of 15,348.14% and a negative return on equity of 64.54%.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.